Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX-1401 in combination with Resiquimod and/or Poly-ICLC · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CDX-1401 in combination with Resiquimod and/or Poly-ICLC | BIOLOGICAL | CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks. |
| CDX-1401 | BIOLOGICAL | - |
| Resiquimod | BIOLOGICAL | - |
| poly-ICLC | BIOLOGICAL | - |
Inclusion Criteria: Among other criteria, patients must meet all of the following conditions to be eligible to be in the study: 1. 18 years of age or older. 2. Have a cancer type that is known to express NY-ESO-1, including (but not limited to) cancer of the bladder, breast, ovary, non-small cell ...